Trial Profile
A phase 3 trial comparing efficacy and safety of paclitaxel oral solution (RMX3001) with paclitaxel injection (Taxol®) in patients with advanced gastric cancer who failed previous treatment
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 20 Sep 2022
Price :
$35
*
At a glance
- Drugs Paclitaxels (Primary) ; Paclitaxels (Primary)
- Indications Gastric cancer
- Focus Registrational; Therapeutic Use
- 13 Sep 2022 According to a HaiHe Biopharma media release, Marketing Authorization Application (MAA) for Paclitaxel Oral Solution (RMX3001) in gastric cancer (GC) has been accepted for review by the National Medical Products Administration-Center for Drug Evaluation (NMPA-CDE).
- 13 Sep 2022 According to a HaiHe Biopharma media release, Professor Jin Li from Shanghai East Hospital and Professor Shukui Qin from Nanjing Jinling Hospital is the leading principal investigator of this study.
- 13 Dec 2018 New trial record